Seroatlas · Human Serome Atlas

BDH2

Dehydrogenase/reductase SDR family member 6

Also known as: DHRS6, DHRS6_HUMAN, FLJ13261, PRO20933, SDR15C1, UCPA-OR, UNQ6308

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q9BUT1
Gene: BDH2
Ensembl: ENSG00000164039
Chromosome: 4
Canonical length: 245 aa
Protein class: Enzymes, Metabolic proteins, Predicted intracellular proteins
Subcellular location: Cytosol
Quaternary structure: Homotetramer

OverviewNCBI Gene

Enables 3-hydroxybutyrate dehydrogenase activity and NAD binding activity. Involved in epithelial cell differentiation and fatty acid beta-oxidation. Located in cytosol. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

245 residues, UniProt reviewed canonical sequence.

>Q9BUT1|BDH2
     1  MGRLDGKVII LTAAAQGIGQ AAALAFAREG AKVIATDINE SKLQELEKYP GIQTRVLDVT
    61  KKKQIDQFAN EVERLDVLFN VAGFVHHGTV LDCEEKDWDF SMNLNVRSMY LMIKAFLPKM
   121  LAQKSGNIIN MSSVASSVKG VVNRCVYSTT KAAVIGLTKS VAADFIQQGI RCNCVCPGTV
   181  DTPSLQERIQ ARGNPEEARN DFLKRQKTGR FATAEEIAML CVYLASDESA YVTGNPVIID
   241  GGWSL

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against BDH2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.24
Highest tissue expression: 146 nTPM

Expression across tissuesHPA

Tissue

kidney: 146 nTPM
midbrain: 39 nTPM
choroid plexus: 38 nTPM
liver: 37 nTPM
duodenum: 37 nTPM
basal ganglia: 35 nTPM

Single-cell type

epididymal efferent duct absorptive cells: 78 nCPM
enterocytes: 78 nCPM
retinal pigment epithelial cells: 68 nCPM
decidual stromal cells: 59 nCPM
peritubular myoid cells: 59 nCPM
leydig cells: 52 nCPM

Immune cell

naive CD8 T-cell: 10 nTPM
T-reg: 10 nTPM
naive CD4 T-cell: 9.7 nTPM
MAIT T-cell: 8.8 nTPM
gdT-cell: 7.6 nTPM
naive B-cell: 6.8 nTPM

Brain region

medulla oblongata: 32 nTPM
thalamus: 31 nTPM
hypothalamus: 31 nTPM
choroid plexus: 29 nTPM
cerebellum: 29 nTPM
midbrain: 28 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.38
gnomAD pLI: 0
gnomAD missense Z: 0.5
DepMap mean gene effect: -0.12
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

3-hydroxybutyrate dehydrogenase activity
NAD binding
oxidoreductase activity, acting on the CH-CH group of donors, NAD or NADP as acceptor
4-oxoproline reductase activity

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads BDH2 as an antibody target. Whether an autoantibody or antibody against BDH2 could matter depends on whether native BDH2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

BDH2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label BDH2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...